Immunotherapy combo shows promise for Hard-to-Treat ovarian cancer
NCT ID NCT03275506
First seen Jun 26, 2026 · Last updated Jun 26, 2026
Summary
This phase II trial tested whether adding the immunotherapy drug pembrolizumab (Keytruda) to standard chemotherapy before surgery helps women with stage IV ovarian cancer. 91 participants received either chemo alone or chemo plus pembrolizumab, followed by surgery. The goal was to see if the combination leads to more complete tumor removal. Results could point to a better way to treat advanced ovarian cancer.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Pembrolizumab (Keytruda) plus chemotherapy (carboplatin and paclitaxel), with or without bevacizumab
- What this could lead to
- If it works, this could improve the chance of completely removing the tumor during surgery for women with advanced ovarian cancer.
- What could go wrong
- This is a phase II trial with only 91 participants, so results are preliminary. Adding pembrolizumab may increase side effects without guaranteeing better outcomes.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for FALLOPIAN TUBE CARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
CHRU Jean Minjoz
Besançon, 25030, France
-
CHU Saint-Etienne - Pôle de Cancérologie
Saint-Priest-en-Jarez, 42271, France
-
Centre CARIO-HPCA
Plérin, 22190, France
-
Centre François Baclesse
Caen, 14000, France
-
Centre Georges François Leclerc
Dijon, 21079, France
-
Centre Henri Becquerel
Rouen, 76038, France
-
Centre Hospitalier Départemental Les Oudairies
La Roche-sur-Yon, 85925, France
-
Centre Hospitalier Intercommunal de Créteil
Créteil, 94010, France
-
Centre Hospitalier Régional d'Orléans
Orléans, 45067, France
-
Centre Hospitalier Universitaire Dupuytren
Limoges, 87042, France
-
Centre Jean Perrin
Clermont-Ferrand, 63000, France
-
Centre Léon Bérard
Lyon, 69373, France
-
Clinique Pasteur
Toulouse, 31076, France
-
Groupe Hospitalier Diaconesses-Croix Saint Simon
Paris, 75020, France
-
Hôpital Henri Duffaut
Avignon, 84000, France
-
Hôpital Privé Jean Mermoz
Lyon, 69373, France
-
Hôpitaux Universitaires de Strasbourg
Strasbourg, 67091, France
-
ICO Centre René Gauducheau
Saint-Herblain, 44805, France
-
Institut Claudius Regaud
Toulouse, 31059, France
-
Institut Jean Godinot
Reims, 51056, France
-
Institut Mutualiste Montsouris-Jourdan
Paris, 75674, France
-
Institut Paoli Calmettes
Marseille, 13009, France
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can heated chemotherapy improve ovarian cancer outcomes?
- Can engineered immune cells target a common ovarian cancer protein?
- Experimental pill takes on Hard-to-Treat ovarian cancer
- Targeted drug hunts down cancer cells in advanced bladder cancer trial
- Radiation boost may Re-Sensitize ovarian cancer to PARP inhibitors
- New PET tracer could spot cancers that standard scans overlook